为解决非洲非 1a/1b HCV 1 亚型难诊疗问题，研究发现 NS5A 区域可辅助检测及治疗选择。 在撒哈拉以南非洲地区，非 1a/1b 型丙型肝炎病毒（HCV）1 亚型较为常见。这些变异体在 NS5A 区域存在与耐药相关的自然多态性替代，难以对其进行特征描述和治疗。研究人员 ...

Based upon a successful engagement with the US Food and Drug Administration (FDA) at the End-of-Phase 2 meeting in January 2025, Atea is initiating a global Phase 3 program and expects patient ...

Atea Pharmaceuticals has already laid off a quarter of its workforce so far this year as the biotech prepares to launch a ...

泛基因型非结构蛋白5A（NS5A）抑制剂和5B（NS5B）抑制剂均为丙肝直接抗病毒药物（DAA），已有研究证实，二者联合在慢性HCV感染成人患者中具有协同 ...

Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus (HCV)Patient Enrollment in Global Phase 3 HCV ...